ITGA5 and atherosclerosis: We further treated mgR mice with Itgb1 mAb for 8 weeks, from 4 to 12 weeks of age (Figure 7B), and analyzed a unique chimeric integrin mouse model where the α5 integrin (Itga5) cytoplasmic domain is replaced with that of α2 integrin, resulting in resistance to atherosclerosis and decreased inflammatory activation (18).